reports
Transactions under Novonesis’ share buyback program
Transactions under Novonesis’ share buyback program Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated 1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Please read the full announcement in PDF. Attachment
Transactions under Novonesis’ share buyback program
Transactions under Novonesis’ share buyback program As of June 20th, 2025, Novonesis has purchased an accumulated 1,660,344 shares with a transaction value of DKK 713,0 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million (DKK 746 million) in total during the remainder of 2025. Please read the full announcement in PDF Attachment
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 19, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,343,678 shares, corresponding to 4.98% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...
- Baptiste Salaville
- Hela Zarrouk
Bravida : A good vehicle to make the most of the upturn in Nordic cons...
We are initiating coverage of Bravida with an Outperform rating, a target price of SEK 112 and a Neutral ESG opinion. A leading player in the Nordic multi-technical installations and services market (Top 3), Bravida has a solid business model with recurring business (65% of revenue in services and renovation activities), good profitability (EBITA margin >6%), excellent FCF generation and a healthy balance sheet (Net Debt/EBITDA:1x). The group should leverage these strengths to capture the pick-u...
- Baptiste Salaville
- Hela Zarrouk
Bravida : Un bon véhicule pour profiter de la reprise de la constructi...
Nous initions Bravida à Surperformance avec un OC de 112 SEK et une opinion ESG Neutre. Acteur de premier plan dans le secteur nordique des installations et services multi-techniques (Top 3), Bravida dispose d’un business model solide avec une activité récurrente (65% du CA Services et rénovation), un bon niveau de profitabilité (marge d’EBITA >6%), une excellente génération de FCF et un bilan sain (DN/EBITDA : 1x). Ces atouts devraient lui permettre de capter la reprise de la demande des servic...
- Baptiste Salaville
- Hela Zarrouk
- Baptiste Salaville
- Hela Zarrouk
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...
Telia Company AB: 1 director
A director at Telia Company AB bought 5,600 shares at 35.500SEK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 10, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,753,631 shares, corresponding to 4.85% of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.00% (previously...
Bravida Holding AB: 1 director
A director at Bravida Holding AB maiden bought 3,360 shares at 87.500SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
- ABGSC Telecom Equipment Research
- Oscar Rönnkvist
- Simon Granath
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed ...
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2). Please read the full announcement in PDF. Attachment
Telenor ASA: 1 director
A director at Telenor ASA bought 3,247 shares at 154.000NOK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Combining EVP roles of Human Health Biosolutions and Strategy & Integr...
Combining EVP roles of Human Health Biosolutions and Strategy & Integration As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration. COPENHAGEN, Denmark – After successfully combining into one company, Novonesis is delivering strong results, progressing firmly on the integration, as well as realizing synergies across the company. As a next step on our integration journey, the EVP area of Strategy & Integration will combine with the Human Health Biosolutions sales area. Henrik Joerck Nielsen, currently Executive Vi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.